Table 3.
Discharge Therapy*
| Type 1 MI | |||||||
|---|---|---|---|---|---|---|---|
|
|
|||||||
| All Type 1 MI (n=119) |
NSTEMI (n=104) |
STEMI (n=15) |
Type 2 MI (n=129) |
Myocardial Injury (n=159) |
P1† | P2* | |
| Aspirin | 101 (84.9) | 87 (83.7) | 14 (93.3) | 86 (66.7) | 107 (67.3) | 0.001 | 0.91 |
| Statin | 100 (84.0) | 86 (82.7) | 14 (93.3) | 83 (64.3) | 103 (64.8) | <0.001 | 0.94 |
| Aspirin + Statin | 92 (77.3) | 79 (76) | 13 (86.7) | 68 (52.7) | 83 (52.2) | <0.001 | 0.93 |
| P2Y12 inhibitor | 59 (49.6) | 46 (44.2) | 13 (86.7) | 33 (25.6) | 39 (24.5) | <0.001 | 0.84 |
| Aspirin + P2Y12 inhibitor^ | 58 (48.7) | 45 (43.3) | 13 (86.7) | 31 (24) | 36 (22.6) | <0.001 | 0.78 |
| Anticoagulant‖ | 11 (9.2) | 8 (7.7) | 3 (20.0) | 11 (8.5) | 10 (6.3) | 0.84 | 0.47 |
| Aspirin + P2Y12+ Anticoagulant | 8 (6.7) | 5 (4.8) | 3 (20.0) | 2 (1.6) | 2 (1.3) | 0.05 | 0.99 |
| ACEi / ARB | 63 (52.9) | 53 (51) | 10 (66.7) | 62 (48.1) | 76 (47.8) | 0.44 | 0.97 |
| Beta-Blocker | 78 (65.5) | 70 (67.3) | 8 (53.3) | 88 (68.2) | 94 (59.1) | 0.66 | 0.11 |
| Calcium Channel Blocker | 25 (21) | 22 (21.2) | 3 (20) | 32 (24.8) | 41 (25.8) | 0.48 | 0.85 |
*
Patients who expired in-hospital were excluded
^
Clopidogrel, Prasugrel, Ticagrelor
‖
Warfarin. Enoxaparin, Apixaban, Rivaroxaban, Dabigatran
†
P1: P-value for the comparison of type 2 MI versus type 1 MI
*
P2: P-value for the comparison of type 2 MI versus myocardial injury
ACEi: Angiotensin-converting-enzyme inhibitor, ARB: Angiotensin receptor blocker